Tango Therapeutics, Inc. reported $60M of revenue over the trailing twelve months, +146% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $60M (to Q2 2026). Net income: −$124M, trailing twelve months to Q2 2026. Free cash flow: −$144M, trailing twelve months to Q2 2026. Operating margin: −761%, trailing twelve months to Q3 2025.

TNGXTango Therapeutics, Inc.

Healthcare

$23.82+213% 1Y

$23.82

$6.9152 weeks$32.90

TNGX as reported

Tango Therapeutics, Inc. reported $60M of revenue over the trailing twelve months, +146% on the year before. 8 reported series are charted on this page, each one as filed.

$60M

Revenue, trailing twelve months · to Q2 2026 · +146% against the twelve months before

Net income: −$124M
Net income · −15% year on year · trailing twelve months to Q2 2026
Free cash flow: −$144M
Free cash flow · −3.3% year on year · trailing twelve months to Q2 2026
Operating margin: −761%
Operating margin · trailing twelve months to Q3 2025

Details›

Every series Ryufin has for TNGX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$60M	+146%	Q2 2026
Net income	−$124M	−15%	Q2 2026
EPS	−$0.86	−35%	Q2 2026
Operating margin	−761%	n/a	Q3 2025
Net margin	−712%	n/a	Q3 2025
ROE	−33%	n/a	Q2 2026
ROA	−27%	n/a	Q2 2026
Free cash flow	−$144M	−3.3%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.